华大基因预计2025年净利亏损5.3亿元—6.3亿元，同比减亏

Core Viewpoint - BGI Genomics (华大基因) expects a net profit attributable to shareholders of between -530 million to -630 million yuan for the year 2025, showing a reduction in losses compared to -903 million yuan in the previous year [1] Group 1: Financial Performance - The company anticipates a significant reduction in losses for 2025 compared to the previous year [1] - The expected net profit range for 2025 indicates an improvement in financial performance year-on-year [1] Group 2: Market and Operational Challenges - Market demand fluctuations and intensified industry competition have led to further declines in the prices of terminal services/products [1] - The gross profit margin of some products has decreased significantly compared to the same period last year [1] Group 3: Strategic Adjustments - The company is actively adjusting its main business product structure, focusing on core advantage product lines to ensure steady development [1] - BGI Genomics is implementing cost reduction and efficiency enhancement measures through lean operations, expecting significant reductions in sales, management, and R&D expenses year-on-year [1]